ClinicalTrials.gg
RecruitingNCT06021197Updated Oct 23, 2026

NMDA-enhancing Treatment for Cognitive Dysfunction of Schizophrenia

A Phase 2 interventional study of NMDAE and Placebo Cap in Schizophrenia, sponsored by China Medical University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by China Medical University Hospital · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Schizophrenia by China Medical University Hospital — 8 open to participants now, 8 under way, none of them phase 3. Schizophrenia · China Medical University Hospital.

Planned enrollment
Largest of 14
90 · median 60
Started
2023
the only one that year
Phase 2
14 of 15
8 open now
Registered
13th of 15
by date

Among the 15 studies in Schizophrenia by China Medical University Hospital, this one has the largest planned enrollment of the 14 interventional ones that give a count, is the only one that started in 2023, is one of 14 in phase 2, and was the 13th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

8 of the 15 studies in Schizophrenia by China Medical University Hospital are open now, in 1 country. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Schizophrenia by China Medical University Hospital, or all of them as a file.
02

Study summary

Cognitive impairment, the core psychopathology of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. While cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target, hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.

Read the detailed description

Cognitive impairment, the core psychopathology and the outcome determinant of schizophrenia, usually persists in schizophrenia patients even during symptomatic remission. Cognitive impairment associated with schizophrenia (CIAS) is an important therapeutic target; and hypofunction of N-methyl-D-aspartate receptor (NMDAR) is a key factor of CIAS. Whether NMDAR-enhancing treatment can truly improve cognitive function needs to be tested in schizophrenia patients during symptomatic remission. This study aims to examine the efficacy and safety of an NMDA-enhancer (NMDAE) for the treatment of CIAS in schizophrenia patients during symptomatic remission.

The subjects are the patients with schizophrenia during symptomatic remission. They keep their original treatment and are randomly, double-blindly assigned into two treatment groups for 12 weeks: (1) NMDAE, or (2) placebo. At weeks 0 and 12, 7 cognitive domains will be measured. At weeks 0, 4, 8, and 12, Global Assessment of Function, Quality of Life Scale, various clinical-symptom rating scales, and side effects scales will be measured too.

Chi-square (or Fisher's exact test) will be used to compare differences of categorical variables and t-test (or Mann-Whitney test if the distribution is not normal) for continuous variables between treatment groups. Mean changes from baseline in repeated-measure assessments will be assessed using the generalized estimating equation (GEE). All p values for clinical measures will be based on two-tailed tests with a significance level of 0.05.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • NMDA
  • Symptomatic remission
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a , Fifth Edition, Text Revision (DSM-5 -TR) diagnosis of schizophrenia
  • Fulfill the Remission in Schizophrenia Working Group (RSWG) criteria for remission (Andreasen et al., 2005): each of eight items (delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, passive/apathetic social withdrawal, and lack of spontaneity and flow of conversation) in the Positive and Negative Syndrome Scale (PANSS) (Kay et al., 1987) scoring 3 or lower for 6 months or longer; in addition, have a baseline total score of 59 or lower in the PANSS
  • Are physically healthy and laboratory assessments (including blood routine, biochemical tests) are clinically insignificant;
  • Have been keeping a fixed dose of antipsychotics (excluding clozapine) for at least 6 months, and that is not allowed to change during the 12-week study period
  • Have sufficient education to communicate effectively and are capable of completing the assessments of the study
  • Agree to participate in the study and provide written

Exclusion criteria

Exclusion Criteria:

  • diagnosis of intellectual disability or substance (including alcohol) use disorder
  • History of epilepsy, head trauma, or serious medical or central nervous system diseases (other than schizophrenia) which may interfere with the study
  • Pregnancy or lactation
  • Inability to follow protocol
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    NMDAE

    An NMDA enhancer

    Drug: NMDAE

  • Placebo comparator
    Placebo

    Placebo

    Drug: Placebo Cap

Interventions

  • DrugNMDAE

    Use of an NMDA enhancer for the treatment of CIAS

  • DrugPlacebo Cap

    Use of placebo as a comparator

06

What researchers measure

Primary outcomes

  1. Change of cognitive function composite

    Ten tests for assessment of 7 cognitive domains: 1. speed of processing (assessed by Category Fluency, Trail Marking A, Wechsler Adult Intelligence Scale(WAIS)-III Digit Symbol-Coding) 2. sustained attention (Continuous Performance Test) 3. working memory: verbal (digit span) and nonverbal (spatial span) 4. verbal learning and memory (WMS-III, word listing) 5. visual learning and memory (WMS-III, visual reproduction) 6. reasoning and problem solving (WISC-III, Maze) 7. social cognition (MSCEIT Version 2) For the domain (a. and c.) with more than one test, a composite T score will be calculated by standardizing the average of each T score. Furthermore, a global composite score (for all seven domains) and a neurocognitive composite score (for the first 6 domains) will be also calculated by standardizing the average of the T score (Lane HY et al, JAMA Psychiatry 2013)

    Time frame: Week 0, 12

Secondary outcomes

  1. Change of Global Assessment of Functioning composite

    Assessment of social, occupational, and psychological function. Minimum value: 1, maximum value:100, the higher scores mean better function.

    Time frame: week 0, 4, 8, 12

  2. Change of Quality of Life Scale

    Assessment of life quality. Minimum value: 0, maximum value:126, the higher scores mean a better outcome.

    Time frame: week 0, 4, 8, 12

Other outcomes

  1. Change of Positive and Negative Syndrome Scale (PANSS)

    Assessment of overall symptoms. Minimum value: 30, maximum value:210, the higher scores mean a worse outcome.

    Time frame: week 0, 4, 8, 12

  2. Change of scales for the Assessment of Negative Symptoms (SANS) total score

    Assessment of negative symptoms. Minimum value: 0, maximum value:100, the higher scores mean a worse outcome.

    Time frame: week 0, 4, 8, 12

  3. Change of Positive subscale of PANSS

    Assessment of positive symptoms. Minimum value: 7, maximum value:49, the higher scores mean a worse outcome.

    Time frame: week 0, 4, 8, 12

  4. Change of Negative subscale of PANSS

    Assessment of negative symptoms. Minimum value: 7, maximum value:49, the higher scores mean a worse outcome.

    Time frame: week 0, 4, 8, 12

  5. Change of General Psychopathology subscale of PANSS

    Assessment of general psychopathology. Minimum value: 16, maximum value:112, the higher scores mean a worse outcome.

    Time frame: week 0, 4, 8, 12

  6. Change of Clinical Global Impression

    Assessment of general impression. Minimum value: 1, maximum value:7, the higher scores mean a worse outcome.

    Time frame: week 0, 4, 8, 12

  7. Change of Hamilton Rating Scale for Depression

    Assessment of depressive symptoms. Minimum value: 0, maximum value:52, the higher scores mean a worse outcome.

    Time frame: week 0, 4, 8, 12

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2027, 50 months after the start.

Of 44 non-industry phase 2 interventional studies under Schizophrenia, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 73. This study's planned 50 months is above that.

Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2023
First posted
Sep 1, 2023
StartActual
Oct 12, 2023
Primary completionEst.
Dec 2027
CompletionEst.
Mar 2028
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date and responsible party
1 update, last Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Minor edits only
    + 3 other changes: index terms, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06021197
Collaborators
National Science and Technology Council, Taiwan
Responsible party
Sponsor
First posted
Sep 1, 2023
Start date
Oct 12, 2023
Primary completion
Dec 2027 (estimated)
Completion
Mar 2028 (estimated)
Last update
Oct 23, 2026

Study contacts

Hsien-Yuan Lane, M.D., Ph.D
Contact
hylane@gmail.com
886 4 22052121 ext. 11855

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion